Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: A phase II study

Journal of Clinical Oncology

Volumn 19, Issue 20, 2001, Pages 4048-4053

  Hoskins, P J ^a   Swenerton, K D ^a   Pike, J A ^a   Wong, F ^a   Lim, P ^a   Acquino Parsons, C ^a   Lee, N ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENDOMETRIUM CANCER; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PAPILLARY CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; TREATMENT OUTCOME;

EID: 0035887303     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.20.4048     Document Type: Article

References (28)

1. Uterine papillary serous carcinoma (UPSC): A clinicopathologic study of 30 cases
2. Uterine papillary serous carcinoma: Evaluation of long-term survival in surgically staged patients
3. Uterine papillary serous carcinoma: A clinical study
4. Phase III trial of doxorubicin ± cisplatin in advanced or recurrent endometrial carcinoma: A Gynecological Oncology Group (GOG) study
5. Taxol is active in platinum-resistant endometrial adenocarcinoma
6. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: A Gynecologic Oncology Group study
7. Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer
8. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
9. Non-parametric estimation from incomplete observations
10. Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer: Update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study group trial
11. A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: Preliminary report
12. Evaluation of paclitaxel and carboplatin in patients with endometrial cancer
13. Paclitaxel and cisplatin: An active regimen in metastatic cancer of the endometrium
14. Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: Long-term results of a phase II multicenter study
15. Uterine papillary serous carcinoma: Patterns of metastatic spread
16. The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma
17. Carboplatin (carbo) and paclitaxel (pac) in advanced and recurrent papillary serous uterine carcinoma (UPSC)
18. Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC)
19. Uterine papillary serous carcinoma treated with intraperitoneal cisplatin and intravenous doxorubicin and cyclophosphamide
20. Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide
21. Treatment of recurrent and metastatic endometrial carcinoma with cisplatin and doxorubicin
22. Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma
23. Treatment of advanced endometrial carcinoma with doxorubicin and cisplatin: Effects on both untreated and previously treated patients
24. Adriamycin and cis-diamminedichloroplatinum in the treatment of metastatic endometrial adenocarcinoma
25. Treatment of recurrent endometrial adenocarcinoma with a combination of doxorubicin and cisplatin
26. Randomized trial of doxorubicin plus cisplatin versus doxorubicin plus paclitaxel plus GCSF in patients with advanced or recurrent endometrial cancer
27. An EORTC GCCC randomized phase II trial of doxorubicin versus doxorubicin plus DDP in endometrial cancer